Video
Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer
Author(s):
In Partnership With:
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.
Brufsky says that the approval of pertuzumab would really only change dosing, as many clinicians are already using the drug to treat patients with HER2-positive breast cancer.
